Breast cancer, with a hazard ratio of 0.68 in females between the two diagnostic periods, continues to reflect advances in early detection and personalized treatments, such as HER2-targeted therapies and hormonal interventions, a trend that is in line with outcomes reported in Scandinavian and Western European studies [30,71]. Here, ERBB2 is linked to breast carcinoma.